Bausch & Lomb Alleges Patent Infringement In Sandoz’s Proposed Generic for Bepreve

Bausch & Lomb Inc. and other plaintiffs March 2 filed a complaint in the U.S. District Court for the District of New Jersey alleging Novartis’s Sandoz unit infringed a patent on the eye drug Bepreve (Bausch & Lomb, Inc. v. Sandoz, Inc.).

Bepreve (bepotastine besilate ophthalmic solution) 1.5 percent is a prescription eye drop that relieves itching associated with allergic conjunctivitis, according to Bausch & Lomb’s website. Valeant Pharmaceuticals International Inc. acquired Bausch & Lomb in 2013 11 PLIR 698, 5/31/13.

In January, Sandoz notified Bausch & Lomb that it had filed an abbreviated new drug application ...